Akso Health Group ADR (AHG)vsMercadoLibre Inc. (MELI)
AHG
Akso Health Group ADR
$2.37
+4.37%
HEALTHCARE · Cap: $807.33M
MELI
MercadoLibre Inc.
$1,639.47
+1.70%
CONSUMER CYCLICAL · Cap: $81.72B
Smart Verdict
WallStSmart Research — data-driven comparison
MercadoLibre Inc. generates 195416% more annual revenue ($28.89B vs $14.78M). MELI leads profitability with a 6.9% profit margin vs 0.0%. MELI earns a higher WallStSmart Score of 62/100 (C+).
AHG
Avoid24
out of 100
Grade: F
MELI
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AHG.
Margin of Safety
-654.6%
Fair Value
$267.44
Current Price
$1639.47
$1372.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 36 in profit
Revenue surging 44.6% year-over-year
Large-cap with strong market position
Growing faster than its price suggests
Generating 4.8B in free cash flow
Areas to Watch
4.2% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 12.3x book value
6.9% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bull Case : MELI
The strongest argument for MELI centers on Return on Equity, Revenue Growth, Market Cap. Revenue growth of 44.6% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : AHG
The primary concerns for AHG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MELI
The primary concerns for MELI are Price/Book, Profit Margin, Piotroski F-Score. A P/E of 41.0x leaves little room for execution misses.
Key Dynamics to Monitor
AHG profiles as a value stock while MELI is a hypergrowth play — different risk/reward profiles.
MELI carries more volatility with a beta of 1.53 — expect wider price swings.
MELI is growing revenue faster at 44.6% — sustainability is the question.
MELI generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
MELI scores higher overall (62/100 vs 24/100) and 44.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and integrated patient care services. With a specialization in advanced health technologies, the company is well-positioned to tap into growth opportunities in telehealth and personalized medicine, bolstered by a strong commitment to research and development. Its robust business model and dedication to quality, supported by a skilled team of professionals, make Akso Health Group an appealing investment for institutional investors aiming to navigate the transformative landscape of healthcare.
Visit Website →MercadoLibre Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · USA
MercadoLibre, Inc. operates online trading platforms in Latin America. The company is headquartered in Buenos Aires, Argentina.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?